Papers/PMID:42030222
Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation.
Kidney & blood pressure research2026The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
dapagliflozin — depletes lactate
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner.”
Quoted verbatim from Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation.. - Study
- animal · not in humans
- Population
- male db/db mice given dapagliflozin 4 or 8 mg/kg/day by oral gavage for 10 weeks, against untreated db/db mice
Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation.2026PMID:42030222Permalink